© Parkinson’s UK, July 2019. Parkinson’s is the operating name of the Parkinson’s Disease Society of the United Kingdom. A charity registered in England and Wales (258197) and in Scotland (SC037554)

Parkinson's UK


18 Jul 2018

Parkinson’s UK is pleased to announce the release of the next tranche of funding to US company Neurolixis to continue final pre-clinical studies for NLX-112, a novel serotonin 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia.
In January 2018, Parkinson’s UK announced funding of more than $1million in funding to enable the NLX-112 program to mo...

15 May 2018

We're pleased to announce that Keapstone Therapeutics, a spin-out company formed as part of the Parkinson's Virtual Biotech, now has it's own independent website at www.keapstone.com.  

Keapstone Therapeutics is a single asset biotech developing drugs that target the Nrf2 signalling pathway (KEAP1 inhibitors) for two devastating conditions – Parkinson’s and Motor...

12 Mar 2018

KEAPSTONE THERAPEUTICS was created in February 2017 as a single-asset virtual biotech company, spun out of University of Sheffield with seed funding of £1M provided by Parkinson’s UK.  Keapstone is dedicated to developing a novel series of small molecule activators of the Nrf2-ARE pathway for neuroprotection in Parkinson’s and amyotrophic lateral sclerosis (ALS).  In...

8 Mar 2018

A new collaboration in the efforts to find a new drug candidate to combat Parkinson’s has been announced in the UK today.

The collaboration, formed by leading charity Parkinson’s UK, contract innovation and research organization, Selcia (part of Eurofins), and computational chemistry software and services provider, Cresset Discovery Services, is centred on creating n...

24 Jan 2018

UK-based charity, Parkinson’s UK is set to provide more than $1million in funding to US biotech company, Neurolixis, to accelerate the development of a promising new drug for people with Parkinson’s.

The funding, to be spread over a twelve-month period, will support final pre-clinical studies for NLX-112, a novel serotonin 5-HT1A receptor agonist for the treatment of...

27 Nov 2017

Parkinson’s UK is pleased to announce that it has agreed to provide up to £320,000 additional funding to Keapstone Therapeutics to expand its current research programme to develop molecules with the potential to create drugs that can slow or stop the progression of Parkinson’s.

Keapstone Therapeutics was launched in March 2017 by Parkinson’s UK and the University of...

Please reload